TCN E-Systems Connects Global Study Teams with Vital Patient Recruitment Metrics

Recruitment Software Leader Introduces Smartphone Application and 11 New Languages to TrialCentralNetSM

BOSTON - TCN e-Systems, LLC, the leading provider of software solutions for the entire clinical trial enrollment process, has introduced product enhancements that include mobile connectivity from a smartphone device. The core technology, TrialCentralNetSM, has served as the infrastructure for hundreds of global and domestic clinical studies, and users are now able to make more rapid business decisions regarding trial management through broader access to real-time recruitment metrics.

"We've created a smartphone app to address the needs of clinical teams that rely on our tools for readily accessible, real-time information," said Sarah Mandracchia, director of data management. "The smartphone app provides immediate access to study-goal information, enrollment numbers, key dates, country information, and media metrics, and study teams can now assess key data and make decisions on the go through their iPhone® or Blackberry®."

Over its more than 10-year history, TrialCentralNet has helped maximize recruitment efforts and decrease enrollment timelines by instantly enhancing patient recruitment planning, infrastructure, implementation, management, and reporting. Among the latest enhancements to Version 5.2 is the addition of 11 new languages to the product's language library.

"When you have the strongest tool on the market, you want to make it available to the largest number of people possible," Mandracchia said. "With the addition of these languages, we now cover 80 percent of clinical research professionals in their native languages, which will allow site personnel to focus on recruitment efforts and data management. User satisfaction and compliance are certainly expected to benefit as well."

The TrialCentralNetSM language library now includes Chinese, Dutch, English, French, German, Hindi, Italian, Japanese, Polish, Portuguese, Russian, and Spanish.

"Technological advancements continue to change the way we live and perform our jobs," states Mandracchia. "We're building upon TrialCentralNet's reputation for intuitive use and seamless integration into investigative site, monitor, and clinical team recruitment activities to ease their workloads and speed recruitment. These latest enhancements are an important step in delivering solutions that drive business productivity," according to Mandracchia. "Expectations are higher across the board."

Among TCN e-Systems' earliest and most dedicated clients is BBK Worldwide, the leading global patient recruitment provider, with offices in Boston, Los Angeles, London, and Osaka, Japan.

"TrialCentralNet serves as the technological cornerstone of every patient recruitment campaign we conduct at BBK. We're thrilled our 9,300 users will be able to take advantage of these new benefits," said Matt Kibby, director of global operations, BBK Worldwide. "As more and more countries are implementing direct-to-patient outreach, we need immediate access to real-time metrics in order to make tactical adjustments that preserve the client's ROI, and TrialCentralNet meets that need."

About TCN e-Systems, LLC

TCN e-Systems provides life sciences companies with Web-based process management infrastructure products to support patient recruitment in clinical research studies. TCN e-Systems' core product, TrialCentralNetSM is the industry's first and most comprehensive patient recruitment management system enabling clinical research teams to make better project management decisions throughout a clinical study's lifetime by linking multiple data sources into a metrics-driven resource. Located in Newton, Mass., the company was incubated at BBK Worldwide, the industry-leading international patient recruitment company. With more than 10 years of deployment in hundreds of clinical trial recruitment campaigns, TCN e-Systems' technology is time-tested and proven to deliver faster and more successful patient enrollment.

Suggested Articles

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."

F2G has raised $60.8 million to fund late-phase clinical development of its antifungal agent olorofim and prepare for commercialization.

The deal comes almost two years after Roche dropped the tumor microenvironment modulator after putting it through a clutch of early-phase studies.